Print

Featured Studies Results

HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/342/heal-abc-study-harnessing-e-mindfulness-approaches-for-living-after-breast-cancer

Clinicaltrials.gov identifier:
NCT06748222 (https://clinicaltrials.gov/show/NCT06748222)

Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression

Clinical and Molecular Studies of Li-Fraumeni Syndrome and TP53-Associated Disorders

https://www.facingourrisk.org/research-clinical-trials/study/340/clinical-and-molecular-studies-of-li-fraumeni-syndrome-and-tp53-associated-disorders

Clinicaltrials.gov identifier:
NCT04367246 (https://clinicaltrials.gov/show/NCT04367246)

Surveys, Registries, Interviews
This study will enroll Li-Fraumeni Syndrome patients, family members, and household members. Patients and family/household members may be enrolled with informed consent

Using the Drug eRapa to Prevent the Growth of Polyps in People with Familial Adenomatous Polyposis (SERENTA)

https://www.facingourrisk.org/research-clinical-trials/study/348/study-of-the-drug-erapa-in-people-with-familial-adenomatous-polyposis-serenta

Clinicaltrials.gov identifier:
NCT06950385 (https://clinicaltrials.gov/show/NCT06950385)

Prevention
Prevention study for people with Familial Adenomatous Polyposis (FAP) who have polyps in the colon or rectum

Sexual Health and Rehabilitation Online (SHAREonline): An Educational Intervention for Young Women after Cancer

https://www.facingourrisk.org/research-clinical-trials/study/323/sexual-health-and-rehabilitation-online-shareonline-an-educational-intervention-for-young-women-after-cancer

Clinicaltrials.gov identifier:
NCT06458049 (https://clinicaltrials.gov/show/NCT06458049)

Quality of Life
An online study comparing two educational interventions for female cancer survivors experiencing sexual health changes

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/345/treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib

Clinicaltrials.gov identifier:
NCT06488378 (https://clinicaltrials.gov/show/NCT06488378)

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/344/study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer

Clinicaltrials.gov identifier:
NCT06401421 (https://clinicaltrials.gov/show/NCT06401421)

Treatment
Biomarker study for people with early-stage breast cancer

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

https://www.facingourrisk.org/research-clinical-trials/study/149/promise-registry-a-prostate-cancer-registry-of-outcomes-and-germline-mutations-for-improved-survival-and-treatment-effectiveness

Clinicaltrials.gov identifier:
NCT04995198 (https://clinicaltrials.gov/show/NCT04995198)

Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer

Testing a Shorter Course of Chemo- and Immunotherapy (Without Anthracycline Drugs) for People With Early-Stage Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/343/a-study-testing-shorter-safer-chemo-immunotherapy-without-anthracycline-drugs-for-people-with-early-stage-triple-negative-breast-cancer

Clinicaltrials.gov identifier:
NCT05929768 (https://clinicaltrials.gov/show/NCT05929768)

Treatment
Treatment study for early-stage triple-negative breast cancer

What Happens to Tissue or Blood Samples you Donate as Part of Research?

https://www.facingourrisk.org/research-clinical-trials/study/327/what-happens-to-tissue-or-blood-samples-you-donate-as-part-of-research

Surveys, Registries, Interviews
Survey to share your views on a new method to track research specimens

Pancreatic Cancer Screening Study (CAPS5)

https://www.facingourrisk.org/research-clinical-trials/study/222/pancreatic-cancer-screening-studycaps5

Clinicaltrials.gov identifier:
NCT02000089 (https://clinicaltrials.gov/show/NCT02000089)

Prevention
Screening study for people at high risk for pancreatic cancer

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

https://www.facingourrisk.org/research-clinical-trials/study/101/a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock

Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

Registry for People at Increased Risk for Pancreatic Cancer

https://www.facingourrisk.org/research-clinical-trials/study/331/registry-for-people-at-increased-risk-for-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT06151223 (https://clinicaltrials.gov/show/NCT06151223)

Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/334/study-of-the-drug-olvi-vec-in-women-with-ovarian-cancer

Clinicaltrials.gov identifier:
NCT05281471 (https://clinicaltrials.gov/show/NCT05281471)

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study)

https://www.facingourrisk.org/research-clinical-trials/study/288/testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap

Clinicaltrials.gov identifier:
NCT05552755 (https://clinicaltrials.gov/show/NCT05552755)

Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery

The American Cancer Society’s “VOICES of Black Women” Observational Study

https://www.facingourrisk.org/research-clinical-trials/study/336/the-american-cancer-societys-voices-of-black-women-observational-study

Surveys, Registries, Interviews
Survey for Black women who have never been diagnosed with cancer

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation

Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

https://www.facingourrisk.org/research-clinical-trials/study/339/studying-the-effectiveness-of-new-parp-inhibitor-saruparib-compared-to-current-treatment-options-for-metastatic-prostate-cancer-evopar-pro1

Clinicaltrials.gov identifier:
NCT06120491 (https://clinicaltrials.gov/show/NCT06120491)

Treatment
Treatment study for metastatic, castration-sensitive prostate cancer

Treating Metastatic Pancreatic Cancer Using a New Combination of Chemotherapy Drugs in People with a BRCA1, BRCA2 or PALB2 genetic or tumor mutation (The PLATINUM Trial)

https://www.facingourrisk.org/research-clinical-trials/study/338/treating-metastatic-brca1-brca2-or-palb2-pancreatic-cancer-using-a-new-combination-of-chemotherapy-drugs

Clinicaltrials.gov identifier:
NCT06115499 (https://clinicaltrials.gov/show/NCT06115499)

Treatment
Treatment study for people with metastatic pancreatic cancer and a BRCA1, BRCA2 or PALB2 mutation

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.